Sarepta Therapeutics, Inc. (NASDAQ:SRPT) shared an update on Elevidys (delandistrogene moxeparvovec-rokl), the only approved ...
Sangamo Therapeutics has stacked up $18 million cash from Eli Lilly in a licensing deal that will let the pharma use the ...
Gene therapy companies have faced numerous setbacks over the last few years. What will it take for gene therapies to fulfill ...
21h
GlobalData on MSNAtsena closes $150m in Series C round to progress gene therapyBain Capital’s Life Sciences team led the funding round, with contributions from new investor Wellington Management.
Here is our list of the 11 Best Gene Therapy Stocks to Buy According to Analysts.
We recently published a list of 8 Best Gene-Editing Stocks to Buy. In this article, we are going to take a look at where ...
Explore more
None of the cell and gene therapies that reached the final regulatory submission stage were rejected by the FDA.
Knocking out a single gene reprograms part of the large intestine to function like the nutrient-absorbing small intestine. In ...
Maria Lowe, Ph.D., associate vice president of Pharmaceutical Intelligence at Institute for Clinical and Economic Review ...
The $150 million will also go toward Atsena’s preclinical pipeline and expand the use of the biotech’s spreading AAV.SPR ...
In response to a request from the European Medicines Agency (EMA) following the death of a 16-year-old patient in the U.S., ...
Gene editing is an advanced medical technique within gene therapy that involves precisely modifying an individual’s DNA to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results